Dr Catriona McNeil

Clinical Associate Professor
Medicine, Central Clinical School


Map

Selected publications

Download citations: PDF RTF Endnote

Books

  • McNeil, C., Fletcher, J., Baker, R., Chong, B., Flanagan, D., Gallus, A., Gibbs, H., McLintock, C., Salem, H., Stacey, M. (2012). Cancer Associated Venous Thromboembolism: Summary of best practice recommendations for Australia & New Zealand. Australia: Health Education and Managament Innovations (HEMI).

Book Chapters

  • Butt, A., Caldon, C., McNeil, C., Swarbrick, A., Musgrove, E., Sutherland, R. (2008). Cell cycle machinery: links with genesis and treatment of breast cancer. In Berstein, Lev M.; Santen, Richard J. (Eds.), Innovative Endocrinology of Cancer: Advances in Experimental Medicine and Biology , Vol. 630, (pp. 189-205). USA: Landes Biosciences. [More Information]
  • Sutherland, R., Sergio, C., McNeil, C., Anderson, L., Inman, C., Butt, A., Musgrove, E. (2008). Estrogens, Cell Proliferation and Breast Cancer. In Melmed, S.; Rochefort, H.; Chanson, P.; Christen, Y. (Eds.), Hormonal Control of Cell Cycle: Research and Perspectives in Endocrine Interactions, (pp. 123-138). Germany: Springer. [More Information]

Journals

  • McNeil, C. (2018). A cup of coffee. New England Journal of Medicine, 379(4), 312-313. [More Information]
  • Lacey, J., Lomax, A., McNeil, C., Marthick, M., Levy, D., Kao, S., Nielsen, T., Dhillon, H. (2018). A supportive care intervention for people with metastatic melanoma being treated with immunotherapy: a pilot study assessing feasibility, perceived benefit, and acceptability. Supportive Care in Cancer. [More Information]
  • Levy, D., Dhillon, H., Lomax, A., Marthick, M., McNeil, C., Kao, S., Lacey, J. (2018). Certainty within uncertainty: a qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy. Supportive Care in Cancer. [More Information]
  • Prasanna, T., Beith, J., Kao, S., Boyer, M., McNeil, C. (2018). Dose modifications in adjuvant chemotherapy for solid organ malignancies: A systematic review of clinical trials. Asia-Pacific Journal of Clinical Oncology, 14(3), 125-133. [More Information]
  • Lomax, A., Lim, J., Cheng, R., Sweeting, A., Lowe, P., McGill, N., Shackel, N., Chua, E., McNeil, C. (2018). Immune Toxicity with Checkpoint Inhibition for Metastatic Melanoma: Case Series and Clinical Management. Journal of Skin Cancer, 2018, 9602540. [More Information]
  • Prasanna, T., McNeil, C., Nielsen, T., Parkin, D. (2018). Isolated immune-related pancreatic exocrine insufficiency associated with pembrolizumab therapy. Immunotherapy, 10(3), 171-175. [More Information]
  • Evans, V., van der Sluis, R., Solomon, A., Dantanarayana, A., McNeil, C., Garsia, R., Palmer, S., Fromentin, R., Chomont, N., Sekaly, R., et al (2018). Programmed cell death-1 (PD-1) contributes to the establishment and maintenance of HIV-1 latency. AIDS, 32(11), 1491-1497. [More Information]
  • Lim, J., Lomax, A., McNeil, C., Harrisberg, B. (2018). Uveitis and Papillitis in the Setting of Dabrafenib and Trametinib Therapy for Metastatic Melanoma: A Case Report. Ocular Immunology and Inflammation, 26(4), 628-631. [More Information]
  • Lomax, A., McNeil, C. (2017). Acute management of autoimmune toxicity in cancer patients on immunotherapy: Common toxicities and the approach for the emergency physician. EMA - Emergency Medicine Australasia, 29(2), 245-251. [More Information]
  • McNeil, C. (2017). Banter. Journal of Clinical Oncology, 35(28), 3262-3263. [More Information]
  • Lomax, A., Nielsen, T., Visintin, L., O�Carrigan, B., Honeyball, F., Shum, B., Saw, R., McNeil, C. (2017). Clinical nurse consultant support: Management of patients with melanoma receiving immunotherapy and targeted therapy. Clinical Journal of Oncology Nursing, 21(4), E93-E98. [More Information]
  • Lomax, A., McGuire, H., McNeil, C., Choi, C., Hersey, P., Karikios, D., Shannon, K., Van Hal, S., Carr, U., Crotty, A., Hollingsworth, J., Kim, H., Fazekas de St Groth, B., McGill, N., et al (2017). Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis. International Journal of Rheumatic Diseases, 20(9), 1277-1285. [More Information]
  • Ascierto, P., Del Vecchio, M., Robert, C., Mackiewicz, A., Chiarion-Sileni, V., Arance, A., Lebbe, C., Bastholt, L., Hamid, O., Rutkowski, P., McNeil, C., et al (2017). Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. The Lancet Oncology, 18(5), 611-622. [More Information]
  • McNeil, C., Tattersall, M. (2017). Misunderstandings, mandatory biopsies, and conflicts of interests in clinical trials: a coercive cocktail? The Lancet Oncology, 18(7), 851-852. [More Information]
  • Long, G., Weber, J., Larkin, J., Atkinson, V., Grob, J., Schadendorf, D., Dummer, R., Robert, C., M�rquez-Rodas, I., McNeil, C., et al (2017). Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression Analysis of 2 Phase 3 Clinical Trials. JAMA Oncology, 3(11), 1511-1519. [More Information]
  • McNeil, C., Harnett, P. (2017). Our Faustian pact with the digital world. The Lancet Oncology, 18(2), 171-172. [More Information]
  • Long, G., Atkinson, V., Cebon, J., Jameson, M., Fitzharris, B., McNeil, C., Hill, A., Ribas, A., Atkins, M., Thompson, J., Menzies, A., Guminski, A., Kong, B., Lomax, A., Carlino, M., et al (2017). Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. The Lancet Oncology, 18(9), 1202-1210. [More Information]
  • McNeil, C. (2017). The aftermath of loss. Medical Journal of Australia, 207(11), 476-477.e1. [More Information]
  • Pulvirenti, T., Hong, A., Clements, A., Forstner, D., Suchowersky, A., Guminski, A., McNeil, C., Hersey, P., Fogarty, G., Kefford, R., Long, G., Wang, T. (2016). Acute Radiation Skin Toxicity Associated With BRAF Inhibitors. Journal of Clinical Oncology, 34(3), e17-e20. [More Information]
  • Lomax, A., Ge, L., Anand, S., McNeil, C., Lowe, P. (2016). Bullous pemphigoid-like reaction in a patient with metastatic melanoma receiving pembrolizumab and previously treated with ipilimumab. Australasian Journal of Dermatology, 57(4), 333-335. [More Information]
  • Lomax, A., Beith, J., Bhadri, V., Boyer, M., Grimison, P., Horvath, L., Kao, S., Tattersall, M., Thomas, D., McNeil, C. (2016). Outcomes of patients with non-melanoma solid tumours receiving self-funded pembrolizumab at Chris O'Brien Lifehouse. Internal Medicine Journal, 46(12), 1392-1398. [More Information]
  • Beckers, R., Selinger, C., Vilain, R., Madore, J., Wilmott, J., Harvey, K., Holliday, A., Cooper, C., Robbins, E., Gillett, D., Kennedy, C., Gluch, L., Carmalt, H., Warrier, S., Gee, H., Chan, C., McLean, A., Walker, E., McNeil, C., Beith, J., Scolyer, R., O'Toole, S., et al (2016). Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Histopathology, 69(1), 25-34. [More Information]
  • McNeil, C. (2016). What have we got to lose? American Journal of Clinical Oncology, 34(36), 4443-4444. [More Information]
  • Selinger, C., Cooper, W., Lum, T., McNeil, C., Morey, A., Waring, P., Amanuel, B., Millward, M., Peverall, J., Van Vliet, C., Pavlakis, N., Gill, A., et al (2015). Equivocal ALK fluorescence in-situ hybridization (FISH) cases may benefit from ancillary ALK FISH probe testing. Histopathology, 67(5), 654-663. [More Information]
  • Cheng, R., Cooper, A., Kench, J., Watson, G., Bye, W., McNeil, C., Shackel, N. (2015). Ipilimumab-induced toxicities and the gastroenterologist. Journal of Gastroenterology and Hepatology, 30(4), 657-666. [More Information]
  • Gee, H., Buffa, F., Harris, A., Toohey, J., Carroll, S., Cooper, C., Beith, J., McNeil, C., Carmalt, H., Mak, C., Kennedy, C., O'Toole, S., et al (2015). MicroRNA-Related DNA repair/ cell-cycle genes independently associated with relapse after radiation therapy for early breast cancer. International Journal of Radiation Oncology Biology Physics, 93(5), 1104-1114. [More Information]
  • Long, G., Atkinson, V., Ascierto, P., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J., Rutkowski, P., McNeil, C., et al (2015). Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma. Journal of Translational Medicine, 13(Suppl 1), 1-2. [More Information]
  • Robert, C., Long, G., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al (2015). Nivolumab in Previously Untreated Melanoma without BRAF Mutation. New England Journal of Medicine, 372(4), 320-330. [More Information]
  • Robert, C., Schachter, J., Long, G., Arance, A., Grob, J., Mortier, L., Daud, A., Carlino, M., McNeil, C., Lotem, M., et al (2015). Pembrolizumab versus ipilimumab in advanced melanoma. New England Journal of Medicine, 372(26), 2521-2532. [More Information]
  • Menzies, A., Atkinson, V., Brown, M., Carlino, M., Cebon, J., Guminski, A., Kefford, R., Long, G., McArthur, G., McNeil, C., et al (2015). Sentinel node biopsy for melanoma: The medical oncology perspective. Australian Family Physician, 44(12), 875-876.
  • Xu, H., Yan, M., Patra, J., Natrajan, R., Yan, Y., Swagemakers, S., Tomaszewski, J., Verschoor, S., Millar, E., van der Spek, P., O'Toole, S., McNeil, C., et al (2011). Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers. Breast Cancer Research, 13(1), R9-1-R9-36. [More Information]
  • Roberts, C., Millar, E., O'Toole, S., McNeil, C., Lehrbach, G., Pinese, M., Tobelmann, P., McCloy, R., Musgrove, E., Sutherland, R., et al (2011). Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer. Oncogene, 30(28), 3186-3197. [More Information]
  • Millar, E., Graham, P., McNeil, C., Browne, L., O'Toole, S., Boulghourjian, A., Kearsley, J., Papadatos, G., Delaney, G., Fox, C., et al (2011). Prediction of outcome of early ER + breast cancer is improved using a biomarker panel, which includes Ki-67 and p53. British Journal of Cancer, 105(2), 272-280. [More Information]
  • Lopez-Knowles, E., Zardawi, S., McNeil, C., Millar, E., Crea, P., Musgrove, E., Sutherland, R., O'Toole, S. (2010). Cytoplasmic Localization of beta-Catenin is a Marker of Poor Outcome in Breast Cancer Patients. Cancer Epidemiology Biomarkers and Prevention, 19(1), 301-309. [More Information]
  • Zardawi, S., Zardawi, I., McNeil, C., Millar, E., McLeod, D., Morey, A., Crea, P., Murphy, N., Pinese, M., Lopez-Knowles, E., Hamilton, A., Spillane, A., Lee, C., et al (2010). High Notch1 protein expression is an early event in breast cancer development and is associated with the HER-2 molecular subtype. Histopathology, 56(3), 286-296. [More Information]
  • Murphy, N., Biankin, A., Millar, E., McNeil, C., O'Toole, S., Segara, D., Crea, P., Olayioye, M., Lee, C., Fox, S., et al (2010). Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status. International Journal of Cancer, 126(6), 1445-1453. [More Information]
  • Millar, E., Anderson, L., McNeil, C., O'Toole, S., Pinese, M., Crea, P., Morey, A., Biankin, A., Henshall, S., Musgrove, E., et al (2009). BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast. British Journal of Cancer, 100(1), 123-133. [More Information]
  • Wang, Y., Dean, J., Millar, E., Tran, T., McNeil, C., Burd, C., Henshall, S., Utama, F., Witkiewicz, A., Rui, H., et al (2008). Cyclin D1b is Aberrantly Regulated in Response to Therapeutic Challenge and Promotes Resistance to Estrogen Antagonists. Cancer Research, 68(14), 5628-5638. [More Information]
  • Musgrove, E., Sergio, C., Anderson, L., Inman, C., McNeil, C., Alles, M., Gardiner-Garden, M., Ormandy, C., Butt, A., Sutherland, R. (2008). Identification of downstream targets of estrogen and c-myc in breast cancer cells. Advances in Experimental Medicine and Biology, 617, 445-451. [More Information]
  • Butt, A., Sergio, C., Inman, C., Anderson, L., McNeil, C., Russell, A., Nousch, M., Preiss, T., Biankin, A., Sutherland, R., et al (2008). The estrogen and c-Myc target gene HSPC111 is over-expressed in breast cancer and is associated with poor patient outcome. Breast Cancer Research. [More Information]
  • McNeil, C., Sergio, C., Anderson, L., Inman, C., Eggleton, S., Murphy, N., Millar, E., Crea, P., Kench, J., Alles, M., Ormandy, C., Butt, A., et al (2006). c-Myc overexpression and endocrine resistance in breast cancer. Journal of Steroid Biochemistry and Molecular Biology. [More Information]
  • Butt, A., McNeil, C., Musgrove, E., Sutherland, R. (2005). Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-myc, cyclin D1 and cyclin E. Endocrine-Related Cancer, 12(Supplement), S47-S59. [More Information]
  • Burge, M., Joshua, A., McNeil, C., Hui, R., Boyer, M., Abraham, R. (2005). Retrospective review of pemetrexed with or without platinum in malignant mesothelioma: The Australian 'Special Access Scheme' experience. Asia-Pacific Journal of Clinical Oncology, 1(1), 47-52.

2018

  • McNeil, C. (2018). A cup of coffee. New England Journal of Medicine, 379(4), 312-313. [More Information]
  • Lacey, J., Lomax, A., McNeil, C., Marthick, M., Levy, D., Kao, S., Nielsen, T., Dhillon, H. (2018). A supportive care intervention for people with metastatic melanoma being treated with immunotherapy: a pilot study assessing feasibility, perceived benefit, and acceptability. Supportive Care in Cancer. [More Information]
  • Levy, D., Dhillon, H., Lomax, A., Marthick, M., McNeil, C., Kao, S., Lacey, J. (2018). Certainty within uncertainty: a qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy. Supportive Care in Cancer. [More Information]
  • Prasanna, T., Beith, J., Kao, S., Boyer, M., McNeil, C. (2018). Dose modifications in adjuvant chemotherapy for solid organ malignancies: A systematic review of clinical trials. Asia-Pacific Journal of Clinical Oncology, 14(3), 125-133. [More Information]
  • Lomax, A., Lim, J., Cheng, R., Sweeting, A., Lowe, P., McGill, N., Shackel, N., Chua, E., McNeil, C. (2018). Immune Toxicity with Checkpoint Inhibition for Metastatic Melanoma: Case Series and Clinical Management. Journal of Skin Cancer, 2018, 9602540. [More Information]
  • Prasanna, T., McNeil, C., Nielsen, T., Parkin, D. (2018). Isolated immune-related pancreatic exocrine insufficiency associated with pembrolizumab therapy. Immunotherapy, 10(3), 171-175. [More Information]
  • Evans, V., van der Sluis, R., Solomon, A., Dantanarayana, A., McNeil, C., Garsia, R., Palmer, S., Fromentin, R., Chomont, N., Sekaly, R., et al (2018). Programmed cell death-1 (PD-1) contributes to the establishment and maintenance of HIV-1 latency. AIDS, 32(11), 1491-1497. [More Information]
  • Lim, J., Lomax, A., McNeil, C., Harrisberg, B. (2018). Uveitis and Papillitis in the Setting of Dabrafenib and Trametinib Therapy for Metastatic Melanoma: A Case Report. Ocular Immunology and Inflammation, 26(4), 628-631. [More Information]

2017

  • Lomax, A., McNeil, C. (2017). Acute management of autoimmune toxicity in cancer patients on immunotherapy: Common toxicities and the approach for the emergency physician. EMA - Emergency Medicine Australasia, 29(2), 245-251. [More Information]
  • McNeil, C. (2017). Banter. Journal of Clinical Oncology, 35(28), 3262-3263. [More Information]
  • Lomax, A., Nielsen, T., Visintin, L., O�Carrigan, B., Honeyball, F., Shum, B., Saw, R., McNeil, C. (2017). Clinical nurse consultant support: Management of patients with melanoma receiving immunotherapy and targeted therapy. Clinical Journal of Oncology Nursing, 21(4), E93-E98. [More Information]
  • Lomax, A., McGuire, H., McNeil, C., Choi, C., Hersey, P., Karikios, D., Shannon, K., Van Hal, S., Carr, U., Crotty, A., Hollingsworth, J., Kim, H., Fazekas de St Groth, B., McGill, N., et al (2017). Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis. International Journal of Rheumatic Diseases, 20(9), 1277-1285. [More Information]
  • Ascierto, P., Del Vecchio, M., Robert, C., Mackiewicz, A., Chiarion-Sileni, V., Arance, A., Lebbe, C., Bastholt, L., Hamid, O., Rutkowski, P., McNeil, C., et al (2017). Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. The Lancet Oncology, 18(5), 611-622. [More Information]
  • McNeil, C., Tattersall, M. (2017). Misunderstandings, mandatory biopsies, and conflicts of interests in clinical trials: a coercive cocktail? The Lancet Oncology, 18(7), 851-852. [More Information]
  • Long, G., Weber, J., Larkin, J., Atkinson, V., Grob, J., Schadendorf, D., Dummer, R., Robert, C., M�rquez-Rodas, I., McNeil, C., et al (2017). Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression Analysis of 2 Phase 3 Clinical Trials. JAMA Oncology, 3(11), 1511-1519. [More Information]
  • McNeil, C., Harnett, P. (2017). Our Faustian pact with the digital world. The Lancet Oncology, 18(2), 171-172. [More Information]
  • Long, G., Atkinson, V., Cebon, J., Jameson, M., Fitzharris, B., McNeil, C., Hill, A., Ribas, A., Atkins, M., Thompson, J., Menzies, A., Guminski, A., Kong, B., Lomax, A., Carlino, M., et al (2017). Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. The Lancet Oncology, 18(9), 1202-1210. [More Information]
  • McNeil, C. (2017). The aftermath of loss. Medical Journal of Australia, 207(11), 476-477.e1. [More Information]

2016

  • Pulvirenti, T., Hong, A., Clements, A., Forstner, D., Suchowersky, A., Guminski, A., McNeil, C., Hersey, P., Fogarty, G., Kefford, R., Long, G., Wang, T. (2016). Acute Radiation Skin Toxicity Associated With BRAF Inhibitors. Journal of Clinical Oncology, 34(3), e17-e20. [More Information]
  • Lomax, A., Ge, L., Anand, S., McNeil, C., Lowe, P. (2016). Bullous pemphigoid-like reaction in a patient with metastatic melanoma receiving pembrolizumab and previously treated with ipilimumab. Australasian Journal of Dermatology, 57(4), 333-335. [More Information]
  • Lomax, A., Beith, J., Bhadri, V., Boyer, M., Grimison, P., Horvath, L., Kao, S., Tattersall, M., Thomas, D., McNeil, C. (2016). Outcomes of patients with non-melanoma solid tumours receiving self-funded pembrolizumab at Chris O'Brien Lifehouse. Internal Medicine Journal, 46(12), 1392-1398. [More Information]
  • Beckers, R., Selinger, C., Vilain, R., Madore, J., Wilmott, J., Harvey, K., Holliday, A., Cooper, C., Robbins, E., Gillett, D., Kennedy, C., Gluch, L., Carmalt, H., Warrier, S., Gee, H., Chan, C., McLean, A., Walker, E., McNeil, C., Beith, J., Scolyer, R., O'Toole, S., et al (2016). Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Histopathology, 69(1), 25-34. [More Information]
  • McNeil, C. (2016). What have we got to lose? American Journal of Clinical Oncology, 34(36), 4443-4444. [More Information]

2015

  • Selinger, C., Cooper, W., Lum, T., McNeil, C., Morey, A., Waring, P., Amanuel, B., Millward, M., Peverall, J., Van Vliet, C., Pavlakis, N., Gill, A., et al (2015). Equivocal ALK fluorescence in-situ hybridization (FISH) cases may benefit from ancillary ALK FISH probe testing. Histopathology, 67(5), 654-663. [More Information]
  • Cheng, R., Cooper, A., Kench, J., Watson, G., Bye, W., McNeil, C., Shackel, N. (2015). Ipilimumab-induced toxicities and the gastroenterologist. Journal of Gastroenterology and Hepatology, 30(4), 657-666. [More Information]
  • Gee, H., Buffa, F., Harris, A., Toohey, J., Carroll, S., Cooper, C., Beith, J., McNeil, C., Carmalt, H., Mak, C., Kennedy, C., O'Toole, S., et al (2015). MicroRNA-Related DNA repair/ cell-cycle genes independently associated with relapse after radiation therapy for early breast cancer. International Journal of Radiation Oncology Biology Physics, 93(5), 1104-1114. [More Information]
  • Long, G., Atkinson, V., Ascierto, P., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J., Rutkowski, P., McNeil, C., et al (2015). Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma. Journal of Translational Medicine, 13(Suppl 1), 1-2. [More Information]
  • Robert, C., Long, G., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al (2015). Nivolumab in Previously Untreated Melanoma without BRAF Mutation. New England Journal of Medicine, 372(4), 320-330. [More Information]
  • Robert, C., Schachter, J., Long, G., Arance, A., Grob, J., Mortier, L., Daud, A., Carlino, M., McNeil, C., Lotem, M., et al (2015). Pembrolizumab versus ipilimumab in advanced melanoma. New England Journal of Medicine, 372(26), 2521-2532. [More Information]
  • Menzies, A., Atkinson, V., Brown, M., Carlino, M., Cebon, J., Guminski, A., Kefford, R., Long, G., McArthur, G., McNeil, C., et al (2015). Sentinel node biopsy for melanoma: The medical oncology perspective. Australian Family Physician, 44(12), 875-876.

2012

  • McNeil, C., Fletcher, J., Baker, R., Chong, B., Flanagan, D., Gallus, A., Gibbs, H., McLintock, C., Salem, H., Stacey, M. (2012). Cancer Associated Venous Thromboembolism: Summary of best practice recommendations for Australia & New Zealand. Australia: Health Education and Managament Innovations (HEMI).

2011

  • Xu, H., Yan, M., Patra, J., Natrajan, R., Yan, Y., Swagemakers, S., Tomaszewski, J., Verschoor, S., Millar, E., van der Spek, P., O'Toole, S., McNeil, C., et al (2011). Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers. Breast Cancer Research, 13(1), R9-1-R9-36. [More Information]
  • Roberts, C., Millar, E., O'Toole, S., McNeil, C., Lehrbach, G., Pinese, M., Tobelmann, P., McCloy, R., Musgrove, E., Sutherland, R., et al (2011). Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer. Oncogene, 30(28), 3186-3197. [More Information]
  • Millar, E., Graham, P., McNeil, C., Browne, L., O'Toole, S., Boulghourjian, A., Kearsley, J., Papadatos, G., Delaney, G., Fox, C., et al (2011). Prediction of outcome of early ER + breast cancer is improved using a biomarker panel, which includes Ki-67 and p53. British Journal of Cancer, 105(2), 272-280. [More Information]

2010

  • Lopez-Knowles, E., Zardawi, S., McNeil, C., Millar, E., Crea, P., Musgrove, E., Sutherland, R., O'Toole, S. (2010). Cytoplasmic Localization of beta-Catenin is a Marker of Poor Outcome in Breast Cancer Patients. Cancer Epidemiology Biomarkers and Prevention, 19(1), 301-309. [More Information]
  • Zardawi, S., Zardawi, I., McNeil, C., Millar, E., McLeod, D., Morey, A., Crea, P., Murphy, N., Pinese, M., Lopez-Knowles, E., Hamilton, A., Spillane, A., Lee, C., et al (2010). High Notch1 protein expression is an early event in breast cancer development and is associated with the HER-2 molecular subtype. Histopathology, 56(3), 286-296. [More Information]
  • Murphy, N., Biankin, A., Millar, E., McNeil, C., O'Toole, S., Segara, D., Crea, P., Olayioye, M., Lee, C., Fox, S., et al (2010). Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status. International Journal of Cancer, 126(6), 1445-1453. [More Information]

2009

  • Millar, E., Anderson, L., McNeil, C., O'Toole, S., Pinese, M., Crea, P., Morey, A., Biankin, A., Henshall, S., Musgrove, E., et al (2009). BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast. British Journal of Cancer, 100(1), 123-133. [More Information]

2008

  • Butt, A., Caldon, C., McNeil, C., Swarbrick, A., Musgrove, E., Sutherland, R. (2008). Cell cycle machinery: links with genesis and treatment of breast cancer. In Berstein, Lev M.; Santen, Richard J. (Eds.), Innovative Endocrinology of Cancer: Advances in Experimental Medicine and Biology , Vol. 630, (pp. 189-205). USA: Landes Biosciences. [More Information]
  • Wang, Y., Dean, J., Millar, E., Tran, T., McNeil, C., Burd, C., Henshall, S., Utama, F., Witkiewicz, A., Rui, H., et al (2008). Cyclin D1b is Aberrantly Regulated in Response to Therapeutic Challenge and Promotes Resistance to Estrogen Antagonists. Cancer Research, 68(14), 5628-5638. [More Information]
  • Sutherland, R., Sergio, C., McNeil, C., Anderson, L., Inman, C., Butt, A., Musgrove, E. (2008). Estrogens, Cell Proliferation and Breast Cancer. In Melmed, S.; Rochefort, H.; Chanson, P.; Christen, Y. (Eds.), Hormonal Control of Cell Cycle: Research and Perspectives in Endocrine Interactions, (pp. 123-138). Germany: Springer. [More Information]
  • Musgrove, E., Sergio, C., Anderson, L., Inman, C., McNeil, C., Alles, M., Gardiner-Garden, M., Ormandy, C., Butt, A., Sutherland, R. (2008). Identification of downstream targets of estrogen and c-myc in breast cancer cells. Advances in Experimental Medicine and Biology, 617, 445-451. [More Information]
  • Butt, A., Sergio, C., Inman, C., Anderson, L., McNeil, C., Russell, A., Nousch, M., Preiss, T., Biankin, A., Sutherland, R., et al (2008). The estrogen and c-Myc target gene HSPC111 is over-expressed in breast cancer and is associated with poor patient outcome. Breast Cancer Research. [More Information]

2006

  • McNeil, C., Sergio, C., Anderson, L., Inman, C., Eggleton, S., Murphy, N., Millar, E., Crea, P., Kench, J., Alles, M., Ormandy, C., Butt, A., et al (2006). c-Myc overexpression and endocrine resistance in breast cancer. Journal of Steroid Biochemistry and Molecular Biology. [More Information]

2005

  • Butt, A., McNeil, C., Musgrove, E., Sutherland, R. (2005). Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-myc, cyclin D1 and cyclin E. Endocrine-Related Cancer, 12(Supplement), S47-S59. [More Information]
  • Burge, M., Joshua, A., McNeil, C., Hui, R., Boyer, M., Abraham, R. (2005). Retrospective review of pemetrexed with or without platinum in malignant mesothelioma: The Australian 'Special Access Scheme' experience. Asia-Pacific Journal of Clinical Oncology, 1(1), 47-52.

To update your profile click here. For support on your academic profile contact .